Controversy::Restless legs syndrome


First::journal    Title::pages    Volume::issue    Syndrome::restless    Restless::symptoms    Sleep::sleep

Controversy Some doctors express the view that the incidence of restless leg syndrome is exaggerated by manufacturers of drugs used to treat it.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> Others believe it is an underrecognized and undertreated disorder.<ref name="ChestReview2006"/> Further, GlaxoSmithKline ran advertisements that, while not promoting off-license use of their drug (ropinirole) for treatment of RLS, did link to the Ekbom Support Group website. That website contained statements advocating the use of ropinirole to treat RLS. The ABPI ruled against GSK in this case.<ref>{{#invoke:citation/CS1|citation |CitationClass=news }}</ref>

Another point of confusion is that RLS and delusional parasitosis are entirely different conditions that share part of the Wittmaack-Ekbom syndrome eponym, as both syndromes were described by the same person, Karl-Axel Ekbom.<ref name="WhoNamedIt">Wittmaack-Ekbom syndrome at Who Named It?</ref>

The Restless Legs Syndrome Foundation<ref>* RLS Foundation</ref> received 44% of its $1.4 million in funding from pharmaceutical groups.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref>

Restless legs syndrome sections
Intro   Signs and symptoms   Causes  Mechanism  Diagnosis   Prevention   Treatment  Prognosis  Epidemiology  History  Controversy  See also  References  External links  

PREVIOUS: HistoryNEXT: See also